27th Annual International Lung Cancer Congress®

Activity Overview

Oncology healthcare professionals who treat patients with lung cancer have an increasing array of diagnostic and therapeutic tools at their disposal. These include the use of immunotherapy and targeted therapy in early-stage and locally advanced disease, as well as in metastatic lung cancer. Additionally, new classes of agents have become available, such as bispecific antibodies and antibody-drug conjugates. These developments have the potential to improve outcomes for patients with lung cancer, but also bring new considerations for implementation, including adequate testing and adverse event management.

The 27th Annual International Lung Cancer Congress^® will distill the latest data on targeted agents, immunotherapy, surgery, and radiation oncology for the management of lung cancer. This event also will include a special visionary session with the annual Addario Keynote Lecture and an expert panel discussion on coming trends in lung cancer therapy over the next decade. As in previous years, cutting-edge lectures, multidisciplinary case-based tumor boards, and question-and-answer sessions will allow participants to engage with international and national experts as they share their perspectives and personal experiences of clinical challenges and ongoing controversies in lung cancer management.

This educational activity is an archive of the live presentation held on July 24-25, 2026.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists interested in treating patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe the role of biomarkers and testing strategies to optimize and personalize treatment selection in patients with lung cancer
• Analyze recent clinical trial evidence as well as ongoing trials for the management of patients with lung cancer
• Formulate approaches to integrate monotherapy and combination immunotherapeutic approaches in the management of patients with lung cancer
• Develop strategies to integrate targeted and cytotoxic agents for the management of patients with lung cancer
• Discuss approaches to address disparities in care for patients with lung cancer

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.

This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.

The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.

This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.